We are a Massachusetts-based biotechnology company developing our proprietary immuno-oncology platforms for the treatment of solid tumors, including our Gene Mediated Cytotoxic Immunotherapy (GMCI™) platform and our rQNestin34.5 platform. GMCI™ is an “off-the-shelf” immunotherapy designed to generate a personalized, robust, and precise systemic response from the patient’s own immune system against his or her cancer.
STIMULATION OF A PRECISE AND ROBUST “PERSONALIZED” ATTACK ON CANCER
The immune system plays an important role in controlling cancer – but sometimes it needs help. As cancer grows and becomes stronger, it develops multiple ways to evade the immune system. Oncolytic Immunotherapy is an innovative approach to disrupt the tumor and awaken the immune system – tipping the balance in favor of the patient—and against the cancer.
We are focused on harnessing viruses to fight cancer based on their ability to efficiently infect and kill cells and their ability to stimulate the immune system against the cancer. The viruses that we use have been genetically modified to minimize impact on healthy tissue while maximizing their anti-tumor and immune stimulatory properties.